Data-driven diagnostics maker AllerGenis has signed a non-exclusive agreement with biotechnology firm Luminex to licence xMAP Technology for a new precision food allergy diagnostic assay.
Under the arrangement, AllerGenis will gain the rights to develop, market and sell its assay using the Luminex technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AllerGenis high-throughput, peptide-bead assay is designed to breakdown allergenic proteins into smaller components called epitopes.
The diagnostic then measures the reactivity of a patient’s antibodies to each epitope.
It will deliver a detailed reactivity profile that can offer a comprehensive solution containing accurate information to better evaluate and manage the patient’s food allergies.
AllerGenis claims that its diagnostic assay is more precise than the existing food allergy tests. The commercial launch of the new food allergy diagnostic platform is being planned for this year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAllerGenis CEO Jim Garner said: “Adopting Luminex’s bead-based xMAP technology dramatically increased the power and scope of our food allergy diagnostic.
“We have been able to scientifically demonstrate the ability to identify food allergies with much higher precision over currently available blood tests. We’re very excited to enter into this agreement with Luminex to bring this much-needed technology to the clinical setting as soon as possible.”
The company’s first product using the Luminex xMAP Technology will be a peanut allergy assay.
In addition, the company is working on multiple assays for different food allergens using its epitope-based technology.
AllerGenis diagnostic platform is aimed at diagnosing food allergy and associated severity without exposing the patient directly to the allergen.
It will also be designed to differentiate between sensitivity and allergic disease, as well as identify patient who will naturally outgrow the condition.
The technology can be additionally used to evaluate, manage and monitor therapy progress and therapeutic efficiency.
